Skip to main content

Table 3 RDW distribution as a function of underlying DMARD therapy

From: Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis

DMARD Intake n RDW, mean (SD) p
Methotrexate Yes 222 14,5 (1,44) < 0,001
No 163 14,0 (1,55)  
Sulfasalazine Yes 9 13,7 (1,56) 0,119
No 376 14,3 (1,5)  
Hydroxychloroquine Yes 30 13,9 (1,19) 0,085
No 355 14,4 (1,52)  
Leflunomide Yes 18 14,7 (2,06) 0,429
No 367 14,3 (1,47)  
Azathioprine Yes 6 14,7 (1,23) 0,273
No 379 14,3 (1,51)  
bDMARDs Yes 139 14,2 (1,45) 0,381
No 246 14,4 (1,53)  
  1. RDW distribution as a function of underlying DMARD therapy, significance level at p level ≤ 0,05, bDMARDs biological DMARDs, see tables above, n number of patients in respective groups